Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CMK389 · 2 trials · 2 indications
The Investigator Global assessment (IGA) scale used was vIGA-AD\^TM (Validated Investigator Global Assessment scale for Atopic Dermatitis). The IGA rating scale was used to determine the severity of atopic dermatitis and clinical response to treatment. It reflected a participant's overall disease severity for the whole body based on a 5-point scale. The 5-point scale included: clear, almost clear, mild, moderate, and severe disease. IGA response is defined as clear or almost clear and at least a 2 point-reduction from baseline at week 16.
To assess the effect of CMK389 compared to placebo after 16 weeks of treatment on spirometry (Forced Vital Capacity). Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Percent predicted FVC is the percentage of the age, height and gender adjusted predicted value.
| Arm | Type | Description |
|---|---|---|
| CMK389 10mg/kg i.v. | EXPERIMENTAL | Active |
| Placebo i.v. | PLACEBO_COMPARATOR | Placebo |
| CMK389 300mg s.c. | EXPERIMENTAL | Active |
| Placebo s.c. | PLACEBO_COMPARATOR | Placebo |
| CMK389 | EXPERIMENTAL | CMK389 10 mg/kg i.v. every 4 weeks for a total of 4 doses |
| Placebo | PLACEBO_COMPARATOR | Placebo i.v. every 4 weeks for a total of 4 doses |
| Name | Type | Description |
|---|---|---|
| CMK389 | BIOLOGICAL | Active |
| Placebo | BIOLOGICAL | Placebo Comparator |
Inclusion Criteria: * Adult male or female participants with chronic atopic dermatitis, aged 18 to 65 years, present for at least 1 year before screening. * Participants with Moderate to severe AD defined by IGA score of ≥ 3 (on a scale of 0 to 4, in which 3 is moderate and 4 is severe) at Baseline...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
CMK389 is an investigational monoclonal antibody being studied for the treatment of atopic dermatitis and pulmonary sarcoidosis. It is being developed by Novartis AG (NVS) and is currently in Phase 2 clinical development for both indications.
CMK389 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 2 clinical trials for atopic dermatitis and pulmonary sarcoidosis.
CMK389 is in Phase 2 clinical development. It has completed one Phase 2 trial in chronic pulmonary sarcoidosis and one Phase 2 trial in moderate to severe atopic dermatitis. It is not yet approved by regulatory authorities and remains investigational.
CMK389 has been studied in two completed Phase 2 trials. NCT04064242 evaluated the drug in 62 patients with chronic pulmonary sarcoidosis across the United States, Czechia, Denmark, Germany, Poland, and the United Kingdom. NCT04836858 assessed its efficacy and safety in 71 patients with moderate to severe atopic dermatitis in Czechia, France, Germany, Hungary, Poland, and Spain.
CMK389 is the only name provided for this investigational drug. No alternative names or brand names have been reported for this monoclonal antibody being developed by Novartis for atopic dermatitis and pulmonary sarcoidosis.